HIKMA Pharmaceuticals PLC

Director's Dealing • Jun 8, 2023

National Storage Mechanism | Additional information /*<![CDATA[*/ /**/ /**/ /**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;} .w{size:595.3pt 841.9pt;margin:49.65pt 72.0pt 49.65pt 72.0pt;}div.w{}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:11.0pt;margin-right:0cm; margin-bottom:11.0pt;margin-left:0cm;text-align:center;line-height:normal}.ba{text-decoration: underline}span.bb{font-size:10.0pt;font-family:"Verdana","sans-serif"}table.be{border:solid windowtext 1.0pt}tr.av{page-break-inside:avoid}td.ax{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm}p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:5.65pt;line-height:normal}td.aw{width:432.6pt;border:solid windowtext 1.0pt; padding:0cm 0cm 0cm 0cm} tr.ar{page-break-inside:avoid;height:30.95pt}td.au{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:30.95pt}td.at{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt}td.as{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt}td.aq{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}td.ap{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}tr.al{page-break-inside:avoid;height:37.4pt}td.ao{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:37.4pt}td.an{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt}td.am{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt} tr.aa{page-break-inside:avoid;height:66.25pt}td.ak{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:66.25pt}td.af{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:66.25pt}p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm; margin-bottom:6.0pt;margin-left:23.65pt;text-indent:-18.0pt;line-height:normal}span.aj{font-size:10.0pt;font-family:"Times New Roman","serif"}p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right: 0cm;margin-bottom:6.0pt;margin-left:23.65pt;text-indent:-18.0pt;line-height: normal}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right: 0cm;margin-bottom:6.0pt;margin-left:23.65pt;line-height:normal}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:36.0pt;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm; margin-bottom:6.0pt;margin-left:23.65pt;text-indent:-18.0pt;line-height:normal}td.ab{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:66.25pt}p.bk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;line-height:normal} span.ae{font-size: 10.0pt;font-family:"Verdana","sans-serif"}p.bl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 12.0pt;margin-left:0cm;line-height:normal}p.bm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt}span.y{font-size:10.0pt;line-height:107%;font-family:"Verdana","sans-serif"} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .w{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/

RNS Number : 1186C

Hikma Pharmaceuticals Plc

08 June 2023

Notification and public disclosure of transactions by persons discharging managerial responsibilities

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Douglas Hurt
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Market purchase of 1500 Ordinary Shares by Gillian Hurt, spouse of Douglas Hurt
c)	Price(s) and volume(s)	Price(s): £18.20 Volume(s):1500
d)	Aggregated information -       Volume -       Price -       Total	1500  £18.20  £27,300
e)	Date of the transaction	6 June 2023
f)	Place of the transaction	London Stock Exchange (XLON)

Helen Middlemist, Deputy Company Secretary

+44 (0) 20 7399 2760

8 June 2023

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGCGDLXDGDGXI